Phase 2 Obesity Trial, Recruiting NCT06778850 Sponsor: MindRank AI Ltd Condition: Obesity
Back to Obesity

Phase 2 Obesity Trial, Recruiting

NCT06778850
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 55 years old at the time of signing the consent form, of any gender.
  • People with a Body Mass Index (BMI) between 27 and 45 kg/m² (a measure of body weight relative to height).
  • Male participants with a waist measurement of 90 cm or more, or female participants with a waist measurement of 85 cm or more.

Who may not be able to join:

  • People who have any condition that raises the risk of bleeding, such as hemorrhoids, acute gastritis, or stomach/duodenal ulcers.
  • People who have a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a related hormonal condition (multiple endocrine neoplasia type 2), or who have an inherited condition that increases the risk of this thyroid cancer.
  • People who have a history of pancreas inflammation (pancreatitis) or gallbladder disease with symptoms.
  • People whose blood calcitonin level (a hormone marker measured by a blood test) is above the normal range at screening.
  • People whose blood pressure at screening is too high — specifically, the top number above 160 or the bottom number above 100 mmHg.
  • People whose liver enzyme levels (ALT or AST) are more than twice the upper limit of normal on a blood test at screening.
  • People whose fasting blood fat levels are too high — including triglycerides, total cholesterol, or LDL ("bad") cholesterol above specified thresholds at screening.
  • People who have abnormally high uric acid levels in their blood along with related physical symptoms (people with high uric acid but no symptoms may still be considered).
  • People whose fasting blood sugar level is above 7 mmol/L at screening.
  • People whose kidneys are not filtering blood efficiently enough, based on a calculated kidney function score below a certain level at screening (confirm with trial site).
  • People who have made significant changes to their diet or exercise habits, or whose body weight has changed by 5% or more, in the 3 months before screening.
  • People who have a notable heart rhythm abnormality on an ECG (heart tracing) that the doctor considers a safety concern, or whose ECG shows a specific electrical interval (QTcF) that is too long — above 450 ms for males or above 470 ms for females.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0571-85233836

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
MindRank AI Ltd
Registry
ClinicalTrials.gov
Start date
9 June 2023
Est. completion
15 July 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov